Skip to main content
Top
Published in: Journal of General Internal Medicine 10/2019

01-10-2019 | Anticoagulant

Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study

Authors: Christine Baumgartner, MD, MAS, Judith Maselli, MSPH, Andrew D. Auerbach, MD, MPH, Margaret C. Fang, MD, MPH

Published in: Journal of General Internal Medicine | Issue 10/2019

Login to get access

Abstract

Background

Although guidelines now allow the use of aspirin as an alternative to anticoagulants for venous thromboembolism prophylaxis after knee or hip arthroplasty, there is limited data on contemporary use and outcomes with aspirin.

Objective

To describe the use of pharmacologic thromboprophylaxis and to assess venous thromboembolic risk with aspirin compared with anticoagulation after knee or hip arthroplasty.

Design

Retrospective cohort study using data from the US MedAssets database.

Patients

Adults with a principal discharge diagnosis of knee or hip arthroplasty between January 1, 2013, and December 31, 2014.

Main Measures

We identified charges for medications used for thromboprophylaxis within 7 days after the index surgery from billing records. The primary outcome was postoperative venous thromboembolism identified by International Classification of Diseases, 9th edition codes, from the index hospitalization, rehospitalization within 30 days, or during an outpatient visit within 90 days postoperatively. We compared postoperative thromboembolic risk in patients receiving aspirin-only and those receiving anticoagulants using propensity score–adjusted multivariable logistic regression models.

Key Results

We identified 74,234 patients with knee arthroplasty and 36,192 with hip arthroplasty who received pharmacologic thromboprophylaxis. Aspirin-only was used in 27.9% of all patients, while 24.2% and 24.1% received warfarin or enoxaparin as prophylactic monotherapy, respectively. Postoperative venous thromboembolism occurred in 495 (0.67%) patients undergoing knee arthroplasty and 145 (0.40%) undergoing hip arthroplasty. Aspirin-only was not related to increased odds of postoperative venous thromboembolism compared with anticoagulants in multivariable adjusted analyses (odds ratio [OR] 0.70; 95% confidence interval [CI], 0.56–0.87, and OR 0.93; 95% CI, 0.62–1.38 for knee or hip arthroplasty, respectively).

Conclusions

More than a fourth of all patients received aspirin as the sole antithrombotic agent after knee or hip arthroplasty. Postoperative thromboprophylaxis with aspirin-only was not associated with a higher risk of postoperative venous thromboembolism compared with anticoagulants after hip or knee arthroplasty.
Appendix
Available only for authorised users
Literature
1.
go back to reference Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients; Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S–325S.CrossRefPubMedPubMedCentral Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients; Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S–325S.CrossRefPubMedPubMedCentral
3.
go back to reference Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S–453S.CrossRefPubMed Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S–453S.CrossRefPubMed
4.
go back to reference An VV, Phan K, Levy YD, Bruce WJ. Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplast. 2016;31:2608–2616.CrossRef An VV, Phan K, Levy YD, Bruce WJ. Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplast. 2016;31:2608–2616.CrossRef
5.
go back to reference Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Joint J. 2016;98-b:1056–1061.CrossRefPubMed Wilson DG, Poole WE, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Joint J. 2016;98-b:1056–1061.CrossRefPubMed
6.
go back to reference Chu JN, Maselli J, Auerbach AD, Fang MC. The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty. Thromb Res. 2017;155:65–71.CrossRefPubMedPubMedCentral Chu JN, Maselli J, Auerbach AD, Fang MC. The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty. Thromb Res. 2017;155:65–71.CrossRefPubMedPubMedCentral
7.
go back to reference Belk KW, Laposata M, Craver C. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin. J Thromb Haemost. 2016;14:2148–2157.CrossRefPubMed Belk KW, Laposata M, Craver C. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin. J Thromb Haemost. 2016;14:2148–2157.CrossRefPubMed
8.
go back to reference Blanchette CM, Craver C, Belk KW, Lubeck DP, Rossetti S, Gutierrez B. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US. J Med Econ. 2015;18:303–311.CrossRefPubMed Blanchette CM, Craver C, Belk KW, Lubeck DP, Rossetti S, Gutierrez B. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US. J Med Econ. 2015;18:303–311.CrossRefPubMed
9.
go back to reference Khanna RR, Kim SB, Jenkins I, et al. Predictive value of the present-on-admission indicator for hospital-acquired venous thromboembolism. Med Care. 2015;53:e31–36.PubMed Khanna RR, Kim SB, Jenkins I, et al. Predictive value of the present-on-admission indicator for hospital-acquired venous thromboembolism. Med Care. 2015;53:e31–36.PubMed
10.
go back to reference Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124:386s–392s.CrossRefPubMed Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124:386s–392s.CrossRefPubMed
11.
go back to reference Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:154–162.CrossRefPubMed Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:154–162.CrossRefPubMed
12.
go back to reference Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251:344–350.CrossRefPubMed Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251:344–350.CrossRefPubMed
13.
go back to reference Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304–312.PubMed Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304–312.PubMed
14.
go back to reference Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res. 2014;472:2878–2886.CrossRefPubMedPubMedCentral Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res. 2014;472:2878–2886.CrossRefPubMedPubMedCentral
15.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed
16.
go back to reference D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281.CrossRefPubMed D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281.CrossRefPubMed
17.
go back to reference Deirmengian GK, Heller S, Smith EB, Maltenfort M, Chen AF, Parvizi J. Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. J Arthroplast. 2016;31:2237–2240.CrossRef Deirmengian GK, Heller S, Smith EB, Maltenfort M, Chen AF, Parvizi J. Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. J Arthroplast. 2016;31:2237–2240.CrossRef
18.
go back to reference Shah SS, Satin AM, Mullen JR, Merwin S, Goldin M, Sgaglione NA. Impact of recent guideline changes on aspirin prescribing after knee arthroplasty. J Orthop Surg Res. 2016;11:123.CrossRefPubMedPubMedCentral Shah SS, Satin AM, Mullen JR, Merwin S, Goldin M, Sgaglione NA. Impact of recent guideline changes on aspirin prescribing after knee arthroplasty. J Orthop Surg Res. 2016;11:123.CrossRefPubMedPubMedCentral
19.
go back to reference Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746–747.CrossRefPubMedPubMedCentral Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746–747.CrossRefPubMedPubMedCentral
20.
go back to reference Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother. 2013;47:63–74.CrossRefPubMed Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother. 2013;47:63–74.CrossRefPubMed
21.
go back to reference Parvizi J, Huang R, Restrepo C, et al. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am. 2017;99:91–98.CrossRefPubMed Parvizi J, Huang R, Restrepo C, et al. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am. 2017;99:91–98.CrossRefPubMed
22.
go back to reference Schmidt-Braekling T, Pearle AD, Mayman DJ, Westrich GH, Waldstein W, Boettner F. Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. J Arthroplasty. 2017;32:965–967.CrossRefPubMed Schmidt-Braekling T, Pearle AD, Mayman DJ, Westrich GH, Waldstein W, Boettner F. Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. J Arthroplasty. 2017;32:965–967.CrossRefPubMed
23.
go back to reference Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158:800–806.CrossRefPubMed Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158:800–806.CrossRefPubMed
25.
go back to reference Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018;378:699–707.CrossRefPubMed Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018;378:699–707.CrossRefPubMed
26.
go back to reference Fang MC, Fan D, Sung SH, et al. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. Med Care. 2017;55:e137-e143.CrossRefPubMedPubMedCentral Fang MC, Fan D, Sung SH, et al. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. Med Care. 2017;55:e137-e143.CrossRefPubMedPubMedCentral
27.
go back to reference Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does “excessive” anticoagulation predispose to periprosthetic infection? J Arthroplast. 2007;22:24–28.CrossRef Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does “excessive” anticoagulation predispose to periprosthetic infection? J Arthroplast. 2007;22:24–28.CrossRef
28.
go back to reference Wang Z, Anderson FA Jr, Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PLoS One. 2014;9:e91755.CrossRefPubMedPubMedCentral Wang Z, Anderson FA Jr, Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PLoS One. 2014;9:e91755.CrossRefPubMedPubMedCentral
29.
go back to reference Gutowski CJ, Zmistowski BM, Lonner JH, Purtill JJ, Parvizi J. Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty. J Arthroplast. 2015;30:36–38.CrossRef Gutowski CJ, Zmistowski BM, Lonner JH, Purtill JJ, Parvizi J. Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty. J Arthroplast. 2015;30:36–38.CrossRef
30.
go back to reference Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467:2606–2612.CrossRefPubMedPubMedCentral Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467:2606–2612.CrossRefPubMedPubMedCentral
31.
go back to reference Parvizi J, Huang R, Rezapoor M, Bagheri B, Maltenfort MG. Individualized Risk Model for Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplast. 2016;31:180–186.CrossRef Parvizi J, Huang R, Rezapoor M, Bagheri B, Maltenfort MG. Individualized Risk Model for Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplast. 2016;31:180–186.CrossRef
Metadata
Title
Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study
Authors
Christine Baumgartner, MD, MAS
Judith Maselli, MSPH
Andrew D. Auerbach, MD, MPH
Margaret C. Fang, MD, MPH
Publication date
01-10-2019
Publisher
Springer International Publishing
Keyword
Anticoagulant
Published in
Journal of General Internal Medicine / Issue 10/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05122-3

Other articles of this Issue 10/2019

Journal of General Internal Medicine 10/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.